Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients.

Zheng J, Dong W, Zhang J, Li G, Gong H.

Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):318-25. doi: 10.1093/abbs/gmw012. Epub 2016 Mar 1.

2.

Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer.

Roßner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, Dietel M, Schäfer R, Sers C.

Oncogenesis. 2016 Jan 18;5:e187. doi: 10.1038/oncsis.2015.51.

3.

YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells.

Dey A, Robitaille M, Remke M, Maier C, Malhotra A, Gregorieff A, Wrana JL, Taylor MD, Angers S, Kenney AM.

Oncogene. 2016 Aug 11;35(32):4256-68. doi: 10.1038/onc.2015.491. Epub 2016 Jan 4.

4.

Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.

Su BH, Shieh GS, Tseng YL, Shiau AL, Wu CL.

Oncotarget. 2015 Nov 10;6(35):38308-26. doi: 10.18632/oncotarget.5702.

5.

YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1.

Somasekharan SP, El-Naggar A, Leprivier G, Cheng H, Hajee S, Grunewald TG, Zhang F, Ng T, Delattre O, Evdokimova V, Wang Y, Gleave M, Sorensen PH.

J Cell Biol. 2015 Mar 30;208(7):913-29. doi: 10.1083/jcb.201411047. Epub 2015 Mar 23.

6.
7.

Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma.

Pu L, Jing S, Bianqin G, Ping L, Qindong L, Chenggui L, Feng C, Wenbin K, Qin W, Jinyu D, Qianfeng X, Yu L, Zhiguang T.

Hepat Mon. 2013 Jul 3;13(7):e8918. doi: 10.5812/hepatmon.8918. eCollection 2013.

8.

Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells.

Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL, Ren F, Li GF.

PLoS One. 2013 Aug 15;8(8):e71071. doi: 10.1371/journal.pone.0071071. eCollection 2013.

9.

YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression.

Wu J, Stratford AL, Astanehe A, Dunn SE.

Transl Oncogenomics. 2007 May 11;2:49-65. Print 2007.

10.

Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.

Fujiwara-Okada Y, Matsumoto Y, Fukushi J, Setsu N, Matsuura S, Kamura S, Fujiwara T, Iida K, Hatano M, Nabeshima A, Yamada H, Ono M, Oda Y, Iwamoto Y.

Br J Cancer. 2013 Mar 5;108(4):836-47. doi: 10.1038/bjc.2012.579.

11.

Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Chen KG, Sikic BI.

Clin Cancer Res. 2012 Apr 1;18(7):1863-9. doi: 10.1158/1078-0432.CCR-11-1590. Epub 2012 Feb 16. Review.

12.

Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients.

Kolk A, Jubitz N, Mengele K, Mantwill K, Bissinger O, Schmitt M, Kremer M, Holm PS.

Br J Cancer. 2011 Dec 6;105(12):1864-73. doi: 10.1038/bjc.2011.491. Epub 2011 Nov 17.

13.

Prognostic association of YB-1 expression in breast cancers: a matter of antibody.

Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, Tan PH, Hains P, Valova VA, Huschtscha L, Royds JA, Perez D, Yoon HS, Cohen SB, Robinson PJ, Bay BH, Lasham A, Braithwaite AW.

PLoS One. 2011;6(6):e20603. doi: 10.1371/journal.pone.0020603. Epub 2011 Jun 10.

14.

Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ, Dunn SE.

PLoS One. 2010 Sep 10;5(9). pii: e12661. doi: 10.1371/journal.pone.0012661.

15.

Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR.

BMC Cancer. 2009 Nov 24;9:410. doi: 10.1186/1471-2407-9-410.

16.

Significance of the Y-box proteins in human cancers.

Matsumoto K, Bay BH.

J Mol Genet Med. 2005 Aug 3;1(1):11-7.

17.

Cellular localization of Y-box binding protein 1 in brain tissue of rats, macaques, and humans.

Unkrüer B, Pekcec A, Fuest C, Wehmeyer A, Balda MS, Horn A, Baumgärtner W, Potschka H.

BMC Neurosci. 2009 Mar 26;10:28. doi: 10.1186/1471-2202-10-28.

18.

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP, Dunn SE.

Breast Cancer Res. 2008;10(6):R99. doi: 10.1186/bcr2202. Epub 2008 Nov 27.

19.

Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK, Kohno K, Mitra S, Bhakat KK.

Mol Cell Biol. 2008 Dec;28(23):7066-80. doi: 10.1128/MCB.00244-08. Epub 2008 Sep 22.

20.

Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein.

Bhakat KK, Mantha AK, Mitra S.

Antioxid Redox Signal. 2009 Mar;11(3):621-38. doi: 10.1089/ARS.2008.2198. Review.

Supplemental Content

Support Center